6 results about "Intercellular adhesion molecule" patented technology

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis / prognosis / assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require ahead computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

Methods of diagnosing and monitoring liver diseases are disclosed. The method includes measuring in a blood sample of the subject an amount of Von Willebrand factor (VWF) and at least one protein biomarker selected from the group consisting of sulfhydryl oxidase 1 (QSOX1), complement component C7 (C7), intercellular adhesion molecule- 1 (ICAM) and platelet glycoprotein V (GP5). Kits for diagnosing and monitoring are also disclosed.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

This invention pertains to methods of treating cancer and lymphocyte mediated diseases using Intercellular Adhesion Molecule (ICAM)-modulating agents.

The invention provides application of a CFB (circulating fluid bed) inhibitor Iptacopan in atherosclerosis, the increase of Iptacopan is applicable to clinical atherosclerosis diseases, and in-vitro experiment results show that the CFB inhibitor Iptacopan can remarkably inhibit cell migration and proliferation of foaming human umbilical vein endothelial cells (HUVEC) and accumulation of reactive oxygen species (ROS) and reduce lipid deposition; according to the present invention, with the application of the target CFB, the plaque vulnerability process can be completely intervened, the angiogenesis induced by the oxidative low density lipoprotein (ox-LDL) can be blocked, the adhesion and the chemotaxis of the mononuclear cells can be inhibited by down-regulating the intercellular adhesion molecule-1 and the mononuclear cell chemotactic protein 1 (MCP1), the inflammatory factor expression of interleukin-1 beta (IL1beta) / interleukin-6 (IL6) can be reduced, and the results show that the target CFB can completely intervene the plaque vulnerability process, the inhibitor Iptacopan shows a huge treatment potential.